Sunrest Lifescience Ltd
Incorporated in 2017, Sunrest Lifescience Ltd trades in Health care and Cosmetics products[1]
- Market Cap ₹ 21.5 Cr.
- Current Price ₹ 50.0
- High / Low ₹ 75.0 / 44.6
- Stock P/E 10.7
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2025 | |
---|---|
33.41 | |
30.38 | |
Operating Profit | 3.03 |
OPM % | 9.07% |
0.00 | |
Interest | 0.31 |
Depreciation | 0.10 |
Profit before tax | 2.62 |
Tax % | 23.28% |
2.01 | |
EPS in Rs | 4.68 |
Dividend Payout % | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -21% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2025 | |
---|---|
Equity Capital | |
Reserves | |
Total Liabilities | |
CWIP | |
Investments | |
Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2025 | |
---|---|
1.43 | |
-1.15 | |
-0.33 | |
Net Cash Flow | -0.04 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2025 | |
---|---|
Debtor Days | |
Inventory Days | |
Days Payable | |
Cash Conversion Cycle | |
Working Capital Days | |
ROCE % |
Documents
Announcements
-
Outcome of Board Meeting
30 May 2025 - Sunrest Lifescience approved FY25 audited results; profit ₹199.98L, revenue ₹3312.24L, unmodified audit opinion.
-
Outcome of Board Meeting
30 May 2025 - Approved audited financial results for year ended March 31, 2025; profit ₹199.98L, revenue ₹3312.24L.
-
Updates
14 May 2025 - Sunrest Lifescience confirms non-applicability of SEBI large corporate debt issuance rules as of March 31, 2025.
-
Board Meeting Intimation
13 May 2025 - SUNREST LIFESCIENCE LIMITED has informed about Board Meeting to be held on 27-May-2025 to inter-alia consider and approve the Audited Financial results of the Company …
-
Disclosure under SEBI Takeover Regulations
9 May 2025 - Promoters declare no encumbrance on shares for FY ended March 31, 2025 under SEBI regulations.
Business Overview:[1][2]
SLSL is in the business of trading of Pharmaceutical Product on wholesale and retail basis. It provides OTC brands in healthcare & personal care viz. Capsules, Tablets, Syrup, Ointment, Gel, mouthwash, Solution, Suspension, Dry Powders, and Toothpaste